As partners of our internationally operating clients, we support the successful market access especially of treatments for rare diseases, of ATMPs or of products which set new therapy standards, both on a strategic and operational level.
Our exclusive white paper provides a comprehensive analysis to derive key considerations for the strategic challenges for gene therapies in Germany, with a focus on pricing and reimbursement
With our longstanding AMNOG-expertise we support DiGA-providers with a customized market access strategy – all the way from the development of the value story to successful price negotiations.
